|Day's range||125.05 - 125.45|
Key Insights Using the 2 Stage Free Cash Flow to Equity, Eli Lilly fair value estimate is US$373 Current share price of...
UK chancellor Jeremy Hunt has told drugmakers that the government has no “magic wand” to deal with financial pressures and was unlikely to give into industry demands to pay a significantly higher price for medicines. The government will on Friday unveil reforms worth £650mn to boost the life sciences sector as part of a wider package of measures. Drugmakers have condemned the government for this year increasing a tax on sales of drugs to the NHS to 26.5 per cent, from 5.1 per cent over the past two years.
Data from a phase II study published in JAMA showed that Pfizer's (PFE) danuglipron reduces glycated hemoglobin and fasting plasma glucose (at all doses) and body weight (at the highest doses) at week 16.
Analysts are bullish on Biogen's Alzheimer's drug, Leqembi, projecting it may generate over $10 billion in sales at its peak.
Recently, Zacks.com users have been paying close attention to Lilly (LLY). This makes it worthwhile to examine what the stock has in store.
(Bloomberg) -- European biotech firm Argenx SE is scheduled to release key drug trial data this summer. Deal-hungry Big Pharma is closely watching.Most Read from BloombergHere’s How Much Wealth You Need to Join the Richest 1% GloballyMercedes Sets Out to Make Sexy Vans With Yacht-Like InteriorsJPMorgan Asset Says Markets Are Right to Bet on US Rate CutsDebt-Limit Talks to Intensify as Biden Set to Depart for JapanSeveral major drugmakers keen to expand in immunology have been studying the $23 bi
Key Insights Significantly high institutional ownership implies Eli Lilly's stock price is sensitive to their trading...
Lilly (LLY) expects to launch four new medicines by 2023 end, of which Mounjaro for type II diabetes and cancer drug Jaypirca have already been launched.
Eli Lilly (NYSE: LLY) and Biogen (NASDAQ: BIIB) are both keen to compete in the market for Alzheimer's disease therapies. Biogen's prior attempt at an Alzheimer's medicine to hit the market was a train wreck, but its latest drug seems to be avoiding a repeat. Meanwhile, Eli Lilly has yet to submit its candidate for regulatory review.
The stock market's short-term volatility can sometimes cloud investors' judgment and cause panic selling. In that spirit, we asked three Motley Fool contributors to discuss buy-and-hold-worthy growth stocks. Read on to find out why they picked Axsome Therapeutics (NASDAQ: AXSM), Eli Lilly (NYSE: LLY), and Vertex Pharmaceuticals (NASDAQ: VRTX).
Most investors are comfortable with the idea of businesses like Apple and Microsoft having market caps in excess of $1 trillion. Today, Eli Lilly's market cap is a little north of $410 billion, which puts it among the top handful of big pharma companies. Its trailing 12-month net income is $6.2 billion, and its trailing price-to-earnings ratio is near 69, which is fairly high, but not at bloated tech stock levels.
While some investors are already well versed in financial metrics (hat tip), this article is for those who would like...
Few pharmaceutical giants have performed as well or better than Eli Lilly (NYSE: LLY) in the stock market over the past year. The Indianapolis-based company's secret wasn't its financial results, as they were relatively mild, or even downright disappointing, for much of this period. The market is forward-looking, and with the drugmaker producing several highly promising programs, investors are increasingly excited regarding Eli Lilly's future.
Eli Lilly stock may look expensive, but there's still plenty of value here for long-term investors.
The headline inflation figure rose at the slowest rate in more than two years.
Nektar's (NKTR) Q1 loss is narrower than expected while revenues beat estimates.
Eli Lilly, Verizon Communications, United Parcel Service, Advanced Micro Devices and The Cigna Group are part of the Zacks Analyst Blog.
Today's Research Daily features new research reports on 16 major stocks, including Eli Lilly and Company (LLY), Verizon Communications Inc. (VZ) and United Parcel Service, Inc. (UPS).
Many industry bigwigs reported solid results, with some beating on earnings or revenues or both. As such, pharma ETFs have been in the green over the past month.
Shares of Eli Lilly (NYSE: LLY) climbed 15.3% last month, according to S&P Global Market Intelligence. Promising drug trial developments and a strong outlook from management in its first-quarter report provided the upward momentum to the pharmaceutical stock. Eli Lilly caught Wall Street's attention early in April after announcing positive results from an early clinical trial for an experimental Alzheimer's drug.
The pharmaceutical giant is likely to grow quickly as it is entering a new age of contested markets.
Eli Lilly (NYSE: LLY) is getting a lot of Wall Street attention again. Eli Lilly's drug development pipeline is as big as they come, and that means plenty of new medicines are likely to hit the market in any given period. Within the next year, Lilly could commercialize tirzepatide for obesity, donanemab for Alzheimer's disease, empagliflozin for chronic kidney disease, and lebrikizumab for atopic dermatitis.
Eli Lilly (NYSE: LLY) and Merck (NYSE: MRK) have seen their shares rise by over 17% and 5%, respectively, this year while the S&P 500 Health Care Sector Index has dropped 1.7%. For Merck, it is a pipeline bolstered by vaccines and oncology therapies. For Lilly, it's a weight-loss drug and an Alzheimer's disease therapy that are showing huge potential.
Readers hoping to buy Eli Lilly and Company ( NYSE:LLY ) for its dividend will need to make their move shortly, as the...
Buying pharmaceutical companies with all-around drug portfolios and pipelines is the key to success as an investor.